Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C11H16BNO4.ClH |
Molecular Weight | 273.521 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.NC[C@H]1OB(O)C2=C1C=CC=C2OCCCO
InChI
InChIKey=DADYQGIQOBJGIW-HNCPQSOCSA-N
InChI=1S/C11H16BNO4.ClH/c13-7-10-8-3-1-4-9(16-6-2-5-14)11(8)12(15)17-10;/h1,3-4,10,14-15H,2,5-7,13H2;1H/t10-;/m1./s1
Molecular Formula | C11H16BNO4 |
Molecular Weight | 237.06 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Epetraborole (AN3365 or GSK2251052) is a novel boron-containing antibiotic that inhibits bacterial leucyl tRNA synthetase. It is active against Gram-negative bacteria, including Enterobacteriaceae bearing NDM-1 and KPC carbapenemases, as well as P. aeruginosa. Epetraborole was under development for the treatment of Gram-negative bacterial infections.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Potency and spectrum of activity of AN3365, a novel boron-containing protein synthesis inhibitor, tested against clinical isolates of Enterobacteriaceae and nonfermentative Gram-negative bacilli. | 2013 Jun |
|
Discovery of a novel class of boron-based antibacterials with activity against gram-negative bacteria. | 2013 Mar |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23507283
Epetraborole (AN3365 or GSK2251052) (MIC(50/90), 0.5/1 μg/ml) was active against Enterobacteriaceae, including a subset of Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae strains (MIC(50/90), 1/2 μg/ml). AN3365 inhibited 98.0 and 92.2% of wild-type (MIC(50/90), 2/8 μg/ml) and carbapenem-resistant (MIC(50/90), 4/8 μg/ml) Pseudomonas aeruginosa strains, respectively, at ≤ 8 μg/ml. AN3365 also demonstrated activity against wild-type Acinetobacter baumannii (MIC(50/90), 2/8 μg/ml) and Stenotrophomonas maltophilia (MIC(50/90), 2/4 μg/ml), while it was less active against multidrug-resistant A. baumannii (MIC50/90, 8/16 μg/ml) and Burkholderia cepacia (MIC(50/90), 8/32 μg/ml).
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 01:19:41 GMT 2023
by
admin
on
Sat Dec 16 01:19:41 GMT 2023
|
Record UNII |
MM0NZY12FA
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
860621
Created by
admin on Sat Dec 16 01:19:42 GMT 2023 , Edited by admin on Sat Dec 16 01:19:42 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1234563-16-6
Created by
admin on Sat Dec 16 01:19:41 GMT 2023 , Edited by admin on Sat Dec 16 01:19:41 GMT 2023
|
PRIMARY | |||
|
DBSALT002062
Created by
admin on Sat Dec 16 01:19:42 GMT 2023 , Edited by admin on Sat Dec 16 01:19:42 GMT 2023
|
PRIMARY | |||
|
52918389
Created by
admin on Sat Dec 16 01:19:42 GMT 2023 , Edited by admin on Sat Dec 16 01:19:42 GMT 2023
|
PRIMARY | |||
|
MM0NZY12FA
Created by
admin on Sat Dec 16 01:19:42 GMT 2023 , Edited by admin on Sat Dec 16 01:19:42 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |